title: Assessing resource use in oncology patients: a comparison of analyses based on claims data and medical chart review.
abstract: BACKGROUND
  Provider claims data are used to make medical analyses and decisions, but such databases typically lack important clinical information.
  
  
  OBJECTIVE
  To compare the patterns of use of filgrastim in analyses of a claims database and a medical chart review.
  
  
  METHODS
  We extracted data from the Medicare 5% sample claims database for the years 1996 through 1998 and from a medical chart review of the Oncology Practice Pattern Survey (OPPS) for the same period to determine the patterns of use of filgrastim in patients with non-Hodgkin.s lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone. The analyses were restricted to the first 3 cycles of the chemotherapy.
  
  
  RESULTS
  A total of 414 patients in the Medicare database were treated with 1,360 cycles of chemotherapy. The mean duration of filgrastim use in these patients was 6.6 days. In the OPPS database, 80 patients were treated with 152 cycles of chemotherapy, with a mean duration of filgrastim use of 9.3 days.
  
  
  CONCLUSIONS
  The mean duration of filgrastim use in the OPPS database was greater than that in the Medicare database and was closer to that shown in clinical trials to produce optimal results (approximately 11 days). The actual use of resources may be underestimated in claims databases, owing to their limitations and potential for bias.
authors: Epinomics Research Inc., 1800 North Beauregard St., Suite 150, Alexandria, VA 22311, USA. georgette.semroc@epinomics.com
authors: Georgette N
authors: GN
authors: Semroc
authors: Jonothan C
authors: JC
authors: Tierce
authors: Moshe
authors: M
authors: Fridman
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D002985:Clinical Protocols; D003520:Cyclophosphamide / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D016208:Databases, Factual; D003657:Decision Making; D004317:Doxorubicin / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D004334:Drug Administration Schedule; D017723:Drug Utilization Review; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D007267:Injections; D007345:Insurance Claim Review / Q000706:statistics & numerical data*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008499:Medical Records / Q000706:statistics & numerical data*; D006278:Medicare / Q000706:statistics & numerical data; D009503:Neutropenia / Q000139:chemically induced / Q000191:economics / Q000517:prevention & control; D016522:Oncology Service, Hospital; D010818:Practice Patterns, Physicians'; D011241:Prednisone / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D011994:Recombinant Proteins; D014750:Vincristine / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D000069585:Filgrastim; D011241:Prednisone